Adherence to rectal gel use among mainly ethnic minority young men who have sex with men during a 3-month placebo gel trial: Implications for microbicide research

AIDS and Behavior

Volumn 18, Issue 9, 2014, Pages 1726-1733

  Carballo Diéguez, Alex ^a   Giguere, Rebecca ^a   Dolezal, Curtis ^a   Bauermeister, José ^b   Leu, Cheng Shiun ^a   Valladares, Juan ^a   Frasca, Timothy ^a   Labbett, Rita ^c   Cranston, Ross D ^c   Febo, Irma ^d   Mayer, Kenneth ^e   McGowan, Ian ^f  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^e FENWAY INSTITUTE   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Adherence; HIV prevention; Rectal microbicide; Young men who have sex with men

Indexed keywords

GEL; TOPICAL ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ETHNIC GROUP; ETHNOLOGY; FOLLOW UP; GEL; HIV INFECTIONS; HUMAN; MALE; MALE HOMOSEXUALITY; MEDICATION COMPLIANCE; PSYCHOLOGY; QUESTIONNAIRE; RECTAL DRUG ADMINISTRATION; SEXUALITY; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ADMINISTRATION, RECTAL; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTI-INFECTIVE AGENTS, LOCAL; ETHNIC GROUPS; FOLLOW-UP STUDIES; GELS; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; MEDICATION ADHERENCE; PENNSYLVANIA; QUESTIONNAIRES; SEXUAL PARTNERS; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 84906309867     PISSN: 10907165     EISSN: 15733254     Source Type: Journal    
DOI: 10.1007/s10461-014-0768-1     Document Type: Article

References (23)

1. Stein ZA. Vaginal microbicides and prevention of HIV infection. Lancet. 1994;343(8893):362-3.
2. Agashe H, Hu M, Rohan L. Formulation and delivery of microbicides. Curr HIV Res. 2012;10(1):88-96.
3. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-74.
4. Celum C, Baeten JM. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Curr Opin Infect Dis. 2012;25(1):51-7.
5. Van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS Lond Engl. 2012;26(7):F13-9.
6. Anton PA, Cranston RD, Kashuba A, Hendrix CW, Bumpus NN, Richardson-Harman N, et al. RMP-02/MTN-006: a phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1 % gel compared with oral tenofovir disoproxil fumarate. AIDS Res Hum Retrovir. 2012;28(11):1412-21.
7. McGowan I, Hoesley C, Cranston RD, Andrew P, Janocko L, Dai JY, et al. A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1 % gel (MTN-007). PLoS ONE. 2013;8(4):e60147.
8. Tabet SR, Surawicz C, Horton S, Paradise M, Coletti AS, Gross M, et al. Safety and toxicity of nonoxynol-9 gel as a rectal microbicide. Sex Transm Dis. 1999;26(10):564-71.
9. McGowan I. Rectal microbicide development. Curr Opin HIV AIDS. 2012;7(6):526-33.
10. Carballo-Diéguez A, Dolezal C, Bauermeister JA, O'Brien W, Ventuneac A, Mayer K. Preference for gel over suppository as delivery vehicle for a rectal microbicide: results of a randomised, crossover acceptability trial among men who have sex with men. Sex Transm Infect. 2008;84(6):483-7.
11. Carballo-Diéguez A, Exner T, Dolezal C, Pickard R, Lin P, Mayer KH. Rectal microbicide acceptability: results of a volume escalation trial. Sex Transm Dis. 2007;34(4):224-9.
12. Celentano DD, Sifakis DF, Hylton DJ, Torian DLV, Guillin DV, Koblin DBA. Race/ethnic differences in HIV prevalence and risks among adolescent and young adult men who have sex with men. J Urban Health. 2005;82(4):610-21.
13. Sifakis F, Hylton JB, Flynn C, Solomon L, MacKellar DA, Valleroy LA, et al. Racial disparities in HIV incidence among young men who have sex with men. JAIDS J Acquir Immune Defic Syndr. 2007;46(3):343-8.
14. Centers for Disease Control and Prevention. CDC - HIV transmission - HIV basics - HIV/AIDS [Internet]. 2013 [cited 2013 May 21]. http://www.cdc.gov/hiv/ basics/transmission.html.
15. Carballo-Diéguez A, Remien RH, Dolezal C, Wagner G. Reliability of sexual behavior self-reports in male couples of discordant HIV status. J Sex Res. 1999;36(2):152-8.
16. Pool R, Montgomery CM, Morar NS, Mweemba O, Ssali A, Gafos M, et al. A mixed methods and triangulation model for increasing the accuracy of adherence and sexual behaviour data: the Microbicides Development Programme. PLoS ONE. 2010;5(7):e11600.
17. Microbicide Trials Network. Backgrounder | microbicide trials network [Internet]. MTN-017: phase II safety and acceptability study of tenofovir gel reformulated for rectal use. 2012 [cited 2013 May 21]. http://www.mtnstopshiv. org/news/studies/mtn017/backgrounder.
18. Eaton L, Kalichman SC, Cain D, Cherry C, Stearns H, Amaral C, et al. Serosorting sexual partners and continued risk for HIV transmission among men who have sex with men. Am J Prev Med. 2007;33(6):479-85.
19. ® and two placebo gels among ethnically diverse, sexually active young women participating in a phase 1 microbicide study. AIDS Behav. 2012;16(7):1761-74.
20. Keller MJ, Buckley N, Katzen LL, Walsh J, Friedland B, Littlefield S, et al. Use of the dye stain assay and ultraviolet light test for assessing vaginal insertion of placebo-filled applicators before and after sex. Sex Transm Dis. 2013;40(12):939-43.
21. Mauck CK, Schwartz JL. Dyeing to know: the use of vaginal applicator staining and other techniques to assess adherence to product use in microbicide trials. Sex Transm Dis. 2012;39(9):713-5.
22. Moench TR, O'Hanlon DE, Cone RA. Evaluation of Microbicide Gel Adherence Monitoring Methods. Sex Transm Dis. 2012;39(5):335-40.
23. Van der Straten A, Cheng H, Mensch B, Friedland B, Katzen L, Littlefield S, et al. Evaluation of 3 approaches for assessing adherence to vaginal gel application in clinical trials. Sex Transm Dis. 2013;40(12):950-6.